Gamma Interferon Mediates Experimental Cerebral Malaria by Signaling within Both the Hematopoietic and Nonhematopoietic Compartments

Ana Villegas-Mendez,a Patrick Strangward,a Tovah N. Shaw,a Ivana Rajkovic,a Vinko Tosevski,b Ruth Forman,a Werner Muller,a Kevin N. Coupera

Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdoma; Institute of Experimental Immunology, Inflammation Research Unit, University of Zurich, Zurich, Switzerlandb

ABSTRACT Experimental cerebral malaria (ECM) is a gamma interferon (IFN-γ)-dependent syndrome. However, whether IFN-γ promotes ECM through direct and synergistic targeting of multiple cell populations or by acting primarily on a specific responsive cell type is currently unknown. Here, using a panel of cell- and compartment-specific IFN-γ receptor 2 (IFN-γR2)-deficient mice, we show that IFN-γ causes ECM by signaling within both the hematopoietic and nonhematopoietic compartments. Mechanistically, hematopoietic and nonhematopoietic compartment-specific IFN-γR signaling exerts additive effects in orchestrating intracerebral inflammation, leading to the development of ECM. Surprisingly, mice with specific deletion of IFN-γR2 expression on myeloid cells, T cells, or neurons were completely susceptible to terminal ECM. Utilizing a reductionist in vitro system, we show that synergistic IFN-γ and tumor necrosis factor (TNF) stimulation promotes strong activation of brain blood vessel endothelial cells. Combined, our data show that within the hematopoietic compartment, IFN-γ causes ECM by acting redundantly or by targeting non-T cell or non-myeloid cell populations. Within the nonhematopoietic compartment, brain endothelial cells, but not neurons, may be the major target of IFN-γ leading to ECM development. Collectively, our data provide information on how IFN-γ mediates the development of cerebral pathology during malaria infection.

KEYWORDS malaria, IFN-γ, cerebral malaria, brain, pathology, immunopathology

Plasmodium berghei ANKA infection of susceptible strains of mice leads to the development of a fatal cerebral pathology, termed experimental cerebral malaria (ECM). Despite some debate, this murine infection model represents the best and most widely utilized animal model for human cerebral malaria (HCM), which is the major cause of morbidity and mortality of humans infected with Plasmodium falciparum (1–4). Although the pathogenesis of ECM is still not fully understood, it is well established that gamma interferon (IFN-γ) plays a central role in the development of the condition (5). Thus, IFN-γ and IFN-γ receptor (IFN-γR)-deficient mice on susceptible backgrounds are fully protected against the development of cerebral pathology (6–8). The resistance of IFN-γR-deficient animals is associated with attenuated parasite accumulation in the brain (9, 10), reduced migration (and/or retention) of leukocytes within the brain (7, 11), decreased chemokine expression in the brain (7, 12), lowered activation of cerebral microvessels (6, 7), and decreased cross-presentation of parasite antigens by cerebral endothelial cells (13). We have shown that IFN-γ production solely by CD4+ T cells is sufficient to cause ECM during P. berghei ANKA infection (14). However, the cell populations directly targeted by IFN-γ during P. berghei ANKA infection, thus promoting the development of ECM, are presently unknown.
The functional IFN-γR, a heterodimeric complex composed of the IFN-γ receptor 1 (IFN-γR1) and IFN-γR2 chains, can be expressed on many different cell types (15, 16). IFN-γR1, the major ligand binding subunit, is ubiquitously expressed, whereas the expression of the nonbinding, signal-transducing IFN-γR2 subunit is generally low and is tightly controlled (15, 16). Consequently, IFN-γR2 expression, rather than IFN-γR1 expression, controls the responsiveness of cells to IFN-γ (15, 17). In nonmalaria models, it has been shown that IFN-γ enhances antigen processing, major histocompatibility complex (MHC) and costimulatory marker expression, and cytokine production in dendritic cells and macrophages/monocytes (15, 16). IFN-γ can also act on T cells, orchestrating CD4+ T cell and CD8+ T cell activation and differentiation, as well as apoptosis (18–24). Moreover, IFN-γ can directly modify the function and status of brain-resident and –specialized cell populations, including neurons, brain endothelial cells, microglial cells, and astrocytes, in a variety of inflammatory settings, including malaria (25–30). Combined, these observations indicate that IFN-γ may mediate ECM development by targeting a specific cell type, in a particular location, at a precise time of infection. Alternatively, it may cause cerebral pathology during malaria infection by functioning within a complex cellular network, acting synergistically on different cell types.

In this study, we have investigated the cell population(s) and compartments that IFN-γ signals within to mediate ECM development during P. berghei ANKA infection. Utilizing novel cell- and compartment-specific IFN-γR2-deficient mice (31), we demonstrate that IFN-γ causes ECM by signaling within both the hematopoietic and nonhematopoietic compartments. Within the brain, IFN-γ signaling within the two compartments was additive, which led to severe neuroinflammation. Within the hematopoietic and nonhematopoietic compartments, IFN-γR2 expression by myeloid cells, T cells, and neurons was, individually, not required for the development of ECM. Importantly, we show that brain endothelial cells were highly responsive to IFN-γ in combination with tumor necrosis factor (TNF). Thus, within the nonhematopoietic compartment, IFN-γ may mediate ECM by directly targeting brain endothelial cells. The results in this study improve our knowledge of the IFN-γ-expressing cell populations that may contribute to the IFN-γ-dependent development of cerebral pathology during malaria infection.

RESULTS

IFN-γ promotes the development of ECM by signaling within both the hematopoietic and nonhematopoietic compartments. To identify the cellular compartments that IFN-γ signals within to mediate the development of ECM, we infected VAV-Cre+ IFN-γR2flox/flox mice (which lack IFN-γR2 expression on all hematopoietic-origin cells) with P. berghei ANKA and compared their susceptibility to ECM with the susceptibilities of globally IFN-γR2−/− mice and wild-type (WT; VAV-Cre+ IFN-γR2flox/flox littermate) mice. WT, globally IFN-γR2−/−, and VAV-Cre+ IFN-γR2flox/flox mice developed comparable peripheral parasite burdens, indicating that neither global nor hematopoietic cell-specific IFN-γR expression contributes to peripheral parasite control during the early phases of P. berghei ANKA infection (Fig. 1A). As expected (6–8, 11), globally IFN-γR2−/− mice were completely resistant to the development of ECM (Fig. 1B to D), whereas almost 100% of WT mice developed signs of late-stage ECM, typically on day 7 of infection (Fig. 1C and D). In contrast, VAV-Cre+ IFN-γR2flox/flox mice displayed intermediate resistance to ECM: all VAV-Cre+ IFN-γR2flox/flox mice developed prodromal signs of ECM (mean score of 3.34 on the grading system) (Fig. 1B), but 60% of the total number of mice used in the study (19/32) were protected from late-stage terminal ECM (Fig. 1C), and in the experiments where survival was specifically assessed, 55% of the VAV-Cre+ IFN-γR2flox/flox mice (6/11) survived the window period of ECM development (days 6 to 12 postinfection) (Fig. 1D). Thus, both hematopoietic and nonhematopoietic IFN-γR signaling contribute toward robust development of terminal late-stage ECM during P. berghei ANKA infection.

IFN-γR signaling within the hematopoietic compartment does not strongly influence splenic immunity during infection. We assessed whether abrogated
IFN-γR2 signaling within the hematopoietic compartment modulated the generation and/or maintenance of innate and adaptive splenic immune responses during infection, contributing to the intermediate resistance of VAV-Cre<sup>−</sup> IFN-γR2<sup>flox/flox</sup> mice to ECM. Within the innate compartment, the numbers of inflammatory monocytes, neutrophils, and classical dendritic cells (CD11b<sup>+</sup> and CD8<sup>+</sup>) were unaltered in the spleens of IFN-γR<sup>−/−</sup> and VAV-Cre<sup>−</sup> IFN-γR2<sup>flox/flox</sup> mice compared with the numbers in WT mice on day 7 of infection (Fig. 2A). In contrast, the numbers of F4/80<sup>+</sup> macrophages were significantly increased in the spleens of IFN-γR<sup>−/−</sup> mice compared with the numbers in VAV-Cre<sup>−</sup> IFN-γR2<sup>flox/flox</sup> mice and WT mice on day 7 of infection (Fig. 2A). Thus, nonhematopoietic and/or any global IFN-γR signaling appears to specifically limit splenic macrophage numbers during <i>P. berghei</i> ANKA infection.

There was a trend toward higher numbers of splenic CD4<sup>+</sup> T cells in IFN-γR<sup>−/−</sup> mice but not in VAV-Cre<sup>−</sup> IFN-γR2<sup>flox/flox</sup> mice compared with the numbers in WT mice on day 7 of infection (Fig. 2B). Similarly, splenic CD8<sup>+</sup> T cell numbers were significantly increased in IFN-γR<sup>−/−</sup> mice but not VAV-Cre<sup>−</sup> IFN-γR2<sup>flox/flox</sup> mice compared with the numbers in WT mice on day 7 of infection (Fig. 2B). Splenic CD4<sup>+</sup> T cell and CD8<sup>+</sup> T cell activation was, however, largely unaltered, as determined by comparing the levels of granzyme B, KLRG-1, and Ki-67 expression in IFN-γR<sup>−/−</sup> mice to the levels in VAV-Cre<sup>−</sup> IFN-γR2<sup>flox/flox</sup> mice and WT mice on day 7 of infection (Fig. 2C). Of the markers examined, only ICOS was differentially expressed by splenic CD4<sup>+</sup> T cells, but not CD8<sup>+</sup> T cells, in IFN-γR<sup>−/−</sup> mice compared with VAV-Cre<sup>−</sup> IFN-γR2<sup>flox/flox</sup> mice and WT mice (Fig. 2C). Combined, these data suggest that hematopoietic IFN-γR signaling does not substantially control the splenic immune response during <i>P. berghei</i> ANKA infection; however, nonhematopoietic and/or synergistic global IFN-γR signaling may affect the numbers but not the general activation of specific splenic innate and adaptive immune cell populations, most probably through promoting cellular apoptosis rather than controlling cellular migration to diverse nonlymphoid tissues (11).

IFN-γR signaling within the hematopoietic and nonhematopoietic compartments synergistically defines the level of cerebral inflammation during infection. Next, we
utilized NanoString gene expression analysis to examine how hematopoietic and nonhematopoietic compartment-specific IFN-γR signaling coordinately shape the inflammatory landscape within the brain during *P. berghei* ANKA infection, promoting ECM development. As expected, the levels of expression of a number of genes associated with interferon signaling, cell adhesion/migration, cytotoxic T lymphocyte (CTL) activity, and innate/endothelial cell activity were significantly elevated within the brains of WT mice experiencing ECM compared with their expression in the brains of ECM-resistant IFN-γR−/− mice (Fig. 3A to E). Notably, the expression of key genes, including those encoding CXCL9, CXCL10, granzyme B, and TAP-1, all of which have been shown to be involved in ECM pathogenesis (32), was dampened rather than completely abrogated in the brains of infected VAV-Cre+/IFN-γR−/− mice compared with their expression in the brains of ECM-resistant IFN-γR−/− mice (Fig. 3A to E). Notably, the expression of key genes, including those encoding CXCL9, CXCL10, granzyme B, and TAP-1, all of which have been shown to be involved in ECM pathogenesis (32), was dampened rather than completely abrogated in the brains of infected VAV-Cre+/IFN-γR−/− mice compared with their expression in the brains of ECM-resistant IFN-γR−/− mice (Fig. 3A to E). Indeed, for all genes identified as differentially expressed in the brains of infected WT mice compared with their expression in infected IFN-γR−/− mice, including those encoding the IFN signaling molecules STAT1, IRF1, IRF7, and IFIT1, intermediate gene expression was observed in the brains of VAV-Cre+/IFN-γR−/− mice compared with their expression in infected WT mice (Fig. 3A to E). Interestingly, although the numbers of intracerebral CD8+ T cells were significantly decreased in infected globally IFN-γR−/− mice compared with the numbers in WT mice on day 7 of infection, potentially contributing to the reduced inflammatory landscape in the brains of globally IFN-γR−/− mice, the numbers of intracerebral CD8+ T cells were comparable in infected VAV-Cre+/IFN-γR−/− mice and WT mice (Fig. 3F). Consequently, these
results suggest that ablation of IFN-γR signaling within the hematopoietic compartment in VAV-Cre IFN-γR2^{−/−} mice led to a generalized reduction of inflammation within the brain during infection, rather than the suppression of individual or specific modules of genes. However, the ameliorated cerebral inflammation in VAV-Cre IFN-γR2^{−/−} mice was not simply due to reduced CD8^{+} T cell accumulation in the brain.

**IFN-γR2 signaling in peripheral myeloid cells and T cells is dispensable for ECM development.** To examine which cell populations respond to IFN-γ within the hema-

---

**FIG 3** IFN-γR signals synergistically within nonhematopoietic and hematopoietic compartments to promote intracerebral inflammation during *P. berghei* ANKA infection. WT, IFN-γR^{−/−}, and VAV-Cre IFN-γR2^{−/−} mice were infected i.v. with 10^4 *P. berghei* ANKA pRBCs. (A to E) On day 7 of infection, brains were removed and expression of selected genes in whole brains was determined by NanoString analysis. Selected genes were grouped according to functional activity, including interferon signaling (A), cell adhesion/migration (B), cytokine response (C), CTL activity (D), and innate/endothelial cell activity (E). Results are presented as log fold change in gene expression compared with mean gene expression in naive brains (with dotted lines representing equivalent magnitude of gene expression as in naive brains). (F) On day 7 of infection, brains were removed and the numbers of CD4^{+} T cells and CD8^{+} T cells were quantified. Results in all panels are the mean values ± SEM of the groups, with 4 to 8 brains per group. For the data shown in panels A to E, brains were obtained from 2 independent experiments. Results in panel F are representative of two independent experiments. *, *P < 0.05 for WT versus IFN-γR2^{−/−} mice; #, *P < 0.05 for WT versus VAV-Cre mice. Statistical significance was tested using one-way ANOVA with Tukey's post hoc test.
toxieotic compartment to mediate IFN-γ-dependent ECM development, we generated CD4-Cre-IFN-γR2²flox/flox and CD4-Cre-IFN-γR2²flox/flox mice (which lack IFN-γR2 expression specifically on CD4 and CD8 T cells) and LysM-Cre-IFN-γR2²flox/flox mice (which lack IFN-γR2 expression specifically on Ly6C and Ly6C monocytes, neutrophils, and most mature macrophage populations). We utilized these mice because, although the splenic T cell and myeloid cell responses were not dramatically attenuated in infected VAV-Cre-IFN-γR2²flox/flox mice (Fig. 2), it was possible that cell-specific IFN-γR signaling controlled T cell and myeloid responses in the brain and other nonlymphoid compartments, influencing the level of neuroinflammation (Fig. 3) and development of ECM. Indeed, we have previously shown that the activation of intracerebral CD4 T cells is reduced in P. berghei ANKA-infected IFN-γR⁻/⁻ mice (11). As expected, CD4-Cre-IFN-γR2²flox/flox and LysM-Cre-IFN-γR2²flox/flox mice developed peripheral parasite burdens similar to those in littermate control (Cre) mice (Fig. 4A). However, importantly, CD4-Cre-IFN-γR2²flox/flox and LysM-Cre-IFN-γR2²flox/flox mice were as susceptible to ECM as littermate control mice, exhibiting mean ECM scores equivalent to those of WT mice (Fig. 4B). Moreover, CD4-Cre-IFN-γR2²flox/flox and LysM-Cre-IFN-γR2²flox/flox mice developed late-stage ECM with frequencies comparable to that of WT mice (total of 18/23, 21/24, and 21/23, respectively) (Fig. 4C). In experiments where survival was specifically assessed, infected CD4-Cre-IFN-γR2²flox/flox and LysM-Cre-IFN-γR2²flox/flox mice also succumbed to ECM with frequencies similar to that of WT mice (total of 9/11, 10/11, and 11/11) (Fig. 4D). Consequently, these results demonstrate that the intermediate resistance of VAV-Cre-IFN-γR2²flox/flox mice was not due to the specific and individual loss of IFN-γR signaling within the T cell or myeloid lineages.

**ECM can develop in the absence of IFN-γR2 signaling in neurons and astrocytes.** The VAV-Cre-IFN-γR2²flox/flox mouse experimental data highlighted an important role for IFN-γR expression by nonhematopoietic cells in promoting terminal ECM development. Neurons express IFN-γR, and IFN-γ can directly induce neuronal damage (25). Neuronal damage has also been reported during P. berghei ANKA infection (33). Thus, to investigate whether IFN-γR signaling within neurons contributes to ECM...
development, we generated Nestin-Cre\(^+\) IFN-\(\gamma\)R2\(^{flox/flox}\) mice, as Nestin-Cre has previously been shown to drive strong Cre-mediated gene recombination in neurons (34). Notably, Nestin-Cre also promotes efficient gene recombination in astrocytes (35), which can be direct target cells of IFN-\(\gamma\)R (5, 26, 28, 29), allowing us to use the Nestin-Cre\(^+\) IFN-\(\gamma\)R2\(^{flox/flox}\) mice to also assess the specific role of IFN-\(\gamma\)R signaling in glial cells in the development of ECM. Nestin-Cre\(^+\) IFN-\(\gamma\)R2\(^{flox/flox}\) mice developed peripheral parasite burdens equivalent to those in littermate control mice (Fig. 5A). In contrast to our expectations, Nestin-Cre\(^+\) IFN-\(\gamma\)R2\(^{flox/flox}\) mice were as susceptible to ECM during \(P.\) berghei ANKA infection as littermate Cre control mice, with all Nestin-Cre\(^+\) IFN-\(\gamma\)R2\(^{flox/flox}\) mice developing late-stage ECM (20/20) and, in experiments where survival was specifically assessed, succumbing to infection on day 7 of infection (10/10) (Fig. 5B to D).

**IFN-\(\gamma\)R synergizes with TNF to activate brain endothelial cells in vitro.** As neuronal (and astrocytic) IFN-\(\gamma\)R2 signaling was not required for ECM development, we addressed which other nonhematopoietic cell populations express IFN-\(\gamma\)R and may respond to IFN-\(\gamma\) to promote cerebral pathology during \(P.\) berghei ANKA infection. Accumulating evidence suggests that brain endothelial cells forming the blood-brain barrier play a pivotal role in ECM pathogenesis through the production of chemokines, cross-presentation of malarial antigens, and regulation of the permeation of materials into the brain tissue (5, 9, 13, 32, 36). Brain Sca-1\(^+\) CD31\(^+\) endothelial cells (gated as shown in Fig. 6A, using the strategy defined in reference 37) expressed the IFN-\(\gamma\)R subunits in naive mice and during ECM (Fig. 6B and C). Therefore, we hypothesized that endothelial cells were the main nonhematopoietic cell population that responds directly to IFN-\(\gamma\), leading to the development of ECM. To examine this, we stimulated brain endothelial cells (bEnd5 cells), which also express IFN-\(\gamma\)R (results not shown), with IFN-\(\gamma\), TNF, or both cytokines in combination. IFN-\(\gamma\) promoted significantly higher upregulation of MHC class I expression by bEnd5 cells than TNF (Fig. 6D and E). Indeed, costimulation with IFN-\(\gamma\) and TNF failed to increase MHC class I expression above that.
induced by IFN-γ by itself (Fig. 6D and E). Of relevance, and as previously reported (32), MHC class I expression by brain endothelial cells was significantly upregulated in WT mice during ECM compared with its expression in naive WT mice (Fig. 6F and G). In contrast, IFN-γ/H9253 was unable to promote VCAM-1 or ICAM-1 expression or interleukin-6 (IL-6) production by brain endothelial cells by itself in vitro and instead only synergized with and amplified the expression and production induced by TNF (Fig. 6H to J). As MHC class I gene expression was significantly lower in the brains of globally IFN-γ/R2/R2 mice and, to a lesser extent, VAV-Cre IFN-γ/R2flox/flox mice compared with its expression in WT mice on day 7 of P. berghei ANKA infection (Fig. 3D), these data in combination indicate that IFN-γ may be the dominant (direct and indirect) driver of MHC class I expression by brain endothelial cells during P. berghei ANKA infection. IFN-γ may also play a pathogenic role by synergizing with other inflammatory cytokines to amplify endothelial cell activation, leading to the development of cerebral pathology.

**FIG 6** IFN-γ promotes direct activation of brain endothelial cells under inflammatory conditions. WT mice were infected i.v. with 10⁴ P. berghei ANKA pRBCs. Brains were removed from infected mice on day 7 of infection and from naive mice. (A to C) Representative plots showing gating strategy to identify brain endothelial cells (A), representative histograms (B), and mean fluorescence intensities (MFI) of IFN-γR1 and IFN-γR2 expression by brain endothelial cells from infected and naive mice (C, FSC, forward scatter; SSC, side scatter). (D, E) Brain endothelial cells (bEnd5 cell line) were cultured in vitro and activated for 18 h with TNF (1 ng/ml) and/or IFN-γ (1 ng/ml). Representative flow cytometry histogram (D) and calculated mean MFI (E) of MHC class I expression by unstimulated and stimulated bEnd5 cells. (F, G) Representative histogram (F) and MFI (G) showing MHC class I expression by brain endothelial cells from P. berghei ANKA-infected and naive mice. (H to J) MFI of VCAM-1 (H) and ICAM-1 (I) on and production of IL-6 (J) by stimulated and unstimulated bEnd5 cells, measured by ELISA. Results in panels C and G are the mean values ± SEM of the groups, with 5 mice per group. Results in panels E and H to J are the mean values ± SEM from three independent biological replicates and are representative of 2 independent experiments. * P < 0.05 between defined groups. Statistical significance was tested using the Mann-Whitney test for the data in panels C and G and one-way ANOVA with Tukey’s post hoc test for the data in panels E and H to J.
DISCUSSION

In this study, we have utilized novel cell- and compartment-specific IFN-γR2−/− mice to examine which cell type(s) IFN-γ targets to cause ECM during P. berghei ANKA infection. We found that VAV-Cre+ IFN-γR2ffox/fox mice displayed intermediate resistance to ECM, with 100% of mice developing prodromal disease and 40% of mice developing late-stage ECM. Thus, we have demonstrated that IFN-γ signals throughout both the hematopoietic and nonhematopoietic compartments to cause ECM.

Notably, abrogation of hematopoietic compartment-specific IFN-γR2 signaling did not significantly modulate the splenic innate or adaptive immune responses during infection. In contrast, hematopoietic and nonhematopoietic IFN-γR2 signaling appeared to function additively to promote malaria-induced cerebral inflammation. As previously reported, IFN-γR2 signaling was critically required for the expression within the brain of a number of chemokine genes (7, 12), as well as genes controlling antigen processing and MHC class I peptide presentation. Unexpectedly, the reduced inflammatory landscape in the brains of infected VAV-Cre+ IFN-γR2ffox/fox mice was not simply due to reduced CD8+ T cell accumulation. Thus, our results are consistent with the model where either redundant global or nonhematopoietic compartment-specific IFN-γR2 signaling recruits CD8+ T cells to the brain during P. berghei ANKA infection, most probably through control of chemokine expression in the brain, as the expression of CXCL9 and CXCL10 was reduced but not abrogated in the brains of VAV-Cre+ IFN-γR2ffox/fox mice. Nonhematopoietic and hematopoietic IFN-γR2 signaling subsequently combine to establish an environment allowing CD8+ T cells to optimally mediate their pathogenic activity. Indeed, we have previously shown that the behavior of intracerebral CD8+ T cells is as important as their presence per se in promoting ECM development (38). Of note, a higher level of brain-to-brain variability in gene expression was observed in the infected VAV-Cre+ IFN-γR2ffox/fox group than in the infected WT or the IFN-γR2−/− group. This likely reflects the heterogeneity in the susceptibilities of VAV-Cre+ IFN-γR2ffox/fox mice to ECM and suggests that ECM develops following breaching of threshold levels of expression of inflammation-related genes. Although we cannot fully exclude the possibility that alterations in immune cell development contributed to the partial resistance of VAV-Cre+ IFN-γR2ffox/fox mice to ECM, the T cell numbers and activation were normal in the spleens and brains of uninfected IFN-γR−/− mice and VAV-Cre+ IFN-γR2ffox/fox mice (results not shown). Thus, we believe it is unlikely that T cell development was significantly affected by global or hematopoietic compartment-specific abrogation of IFN-γR2 expression.

We dissected the targets of IFN-γ within the hematopoietic lineage and determined that IFN-γR signaling within T cells (CD4-Cre) and monocytes/macrophages and neutrophils (LysM-Cre) is (individually) dispensable for the development of ECM. That IFN-γR expression on T cells is not required for the development of ECM was perhaps unsurprising given that we have previously shown that CD8+ T cell activation is largely unimpaired systemically in IFN-γ knockout (KO) mice during P. berghei ANKA infection (11). Moreover, CD4+ T cell activation is altered, to a relatively small degree, only in the brains of IFN-γ KO mice during infection (11). Thus, T cell-intrinsic IFN-γR signaling does not appear to contribute to the development of pathogenic T cell responses during P. berghei ANKA infection. Rather, IFN-γ indirectly promotes the migration to and accumulation of CD8+ T cells within the brain during P. berghei ANKA infection by modulating the expression of chemokines within the tissue (7, 11, 12).

The observation that LysM-Cre+ IFN-γR2ffox/fox mice were as susceptible to ECM as WT mice indicates that IFN-γR signaling within blood-derived monocytes, macrophages, and neutrophils is not required for the development of ECM. These results are thus consistent with the more general observations in the literature that peripheral monocytes and macrophages are not critically involved in the pathogenesis of ECM (9, 39, 40). It is important to note, however, that while LysM-Cre has a high gene recombination rate in peripheral monocytes, macrophages, and neutrophils, it only promotes gene recombination in 50% of microglial cells (41). Moreover, the efficiency...
of VAV-Cre-mediated genetic recombination in microglial cells is debated (42). Consequently, we cannot definitively extrapolate the role of IFN-γR signaling in microglial cells in the development of neuropathology during malaria infection using the Cre-driving lines employed in this study. Nevertheless, utilizing CX3CR1-iDTR mice, in which diphtheria toxin (DT) treatment promotes extensive depletion of microglial cells, perivascular macrophages, and other myeloid cell populations (43), we have recently demonstrated that perivascular macrophages and microglial cells are not involved in the terminal stages of ECM development (38). Consequently, we do not believe that IFN-γR signaling by microglial cells is critically required for ECM development. It remains to be resolved whether IFN-γ acts in a redundant and/or additive manner throughout the hematopoietic compartment to promote ECM or whether it mediates its effects through an as-yet-unidentified hematopoietic cell population.

In terms of the nonhematopoietic cell populations that respond to IFN-γ during P. berghei ANKA infection, our results indicate that neuronal IFN-γR signaling is not crucial for the development of late-stage neuropathology. This suggests that the IFN-γ-dependent effects on neuronal cells observed during ECM (33) must be mediated in trans via activity on other cell types. As Nestin-Cre also exerts strong effects in the astrocyte lineage cells (35), our results also suggest that astrocytic IFN-γR signaling is dispensable for the development of ECM.

Notably, it has recently been shown that IFN-γ promotes cross-presentation of malarial antigens by brain endothelial cells and that this is an important event in ECM pathogenesis (13). Consistent with this, we found that IFN-γR was expressed by brain endothelial cells in naive mice and during P. berghei ANKA infection. Moreover, as has previously been reported, we found that IFN-γ stimulation was able to promote strong upregulation of MHC class I by brain endothelial cells in vitro (13, 44). In addition, the gene expression of MHC class I was lower in the brains of globally IFN-γR2−/− mice and, to a lesser extent, VAV-Cre+ IFN-γR2flox/flox mice than in the brains of WT mice on day 7 of P. berghei ANKA infection. As the VAV-Cre line utilized in this study does not promote gene recombination in vascular endothelial cells (45), our results therefore suggest that IFN-γ may nonredundantly directly and indirectly target brain endothelial cells to control MHC class I expression during P. berghei ANKA infection, leading to the development of ECM. Although IFN-γ, in combination with other inflammatory cytokines, also promoted VCAM-1 and ICAM-1 expression and IL-6 production, the gene expression levels of VCAM-1 and ICAM-1 were not significantly lower in the brains of global IFN-γR2−/− mice and VAV-Cre+ IFN-γR2flox/flox mice than in the brains of WT mice on day 7 of P. berghei ANKA infection. As it has recently been reported that the protein levels of ICAM-1 and VCAM-1 are reduced by brain endothelial cells in IFN-γ−/− mice during P. berghei ANKA infection (46), this may suggest that there is a dichotomy in the gene and protein expression levels of ICAM-1 and VCAM-1 by brain endothelial cells during P. berghei ANKA infection or that gene expression differences specifically by brain endothelial cells in the IFN-γR2-deficient mice were diluted within our whole-brain NanoString analysis. Thus, although we acknowledge the reductionist nature of our in vitro experiments and the fact that they do not fully recapitulate the inflammatory intracerebral environment during ECM, we believe our data, in agreement with previous studies (5, 44), strongly support the hypothesis that brain endothelial cells may be the major nonhematopoietic cell IFN-γ target leading to ECM. In future work, the relative importance of IFN-γ targeting of brain endothelial cells in promoting ECM can be definitively assessed by utilizing Slco1c1-Cre mice (47) crossed with IFN-γR2flox/flox mice.

In summary, the results in this study are consistent with an overall model where IFN-γ acts on different cell populations within the hematopoietic and nonhematopoietic cell compartments to orchestrate brain inflammation that enables CD8+ T cells to manifest their pathogenic activity. It remains to be defined whether IFN-γ acts on the diverse responding cell types in a concomitant or temporal manner to promote ECM. However, our results further argue that IFN-γ predominantly exerts its ECM-inducing pathogenic function locally within the brain, rather than within the spleen. The results
in this study improve our understanding of the responding cell types that orchestrate the IFN-γ-dependent development of ECM.

MATERIALS AND METHODS

Animals and P. berghei ANKA infection. IFN-γR2<sup>−/−</sup> (global), VAV-Cre<sup>−/−</sup> × IFN-γR2<sup>lox/lox</sup>, CD4-Cre<sup>−/−</sup> × IFN-γR2<sup>lox/lox</sup>, LysM-Cre<sup>−/−</sup> × IFN-γR2<sup>lox/lox</sup>, and Nestin-Cre<sup>−/−</sup> × IFN-γR2<sup>lox/lox</sup> mice (all on the C57BL/6 background) were maintained in individual ventilated cages at the University of Manchester. With the exception of Cre<sup>−/−</sup>-littermates, mice with selective IFN-γR2 deficiency and Cre<sup>−/−</sup> (WT) mice were identified by PCR. C57BL/6 mice purchased from Charles River, United Kingdom, were used as controls for IFN-γR2<sup>−/−</sup> mice, and Cre<sup>−/−</sup>-littermates were used as WT controls for all other strains of mice. The generation and characterization of IFN-γR2<sup>lox/lox</sup> mice and the efficiency and specificity of the various Cre deletion strains utilized in the experiments have previously been described (31, 35, 48–50). Importantly, as opposed to other VAV-Cre lines (S1), the VAV-Cre line utilized in this study does not promote gene recombination in vascular endothelial cells (45). All animal work was approved by the University of Manchester Animal Procedures and Ethics Committee and was performed in accordance with the UK Home Office (HO) Animals (Scientific Procedures) Act 1986 (HO project license 70/7293) (S2).

Cryopreserved P. berghei ANKA-GFP (expressing green fluorescent protein) parasites (S3) were thawed and passaged once through C57BL/6 mice before being used to infect experimental animals. Animals were infected via intravenous injections of 1 × 10<sup>6</sup> parasitized red blood cells (pRBCs). Peripheral parasitemia of infected mice were assessed every other day of infection (from day 3 of infection) by microscopic examination of Giemsa-stained thin blood smears. The development of ECM was assessed using a well-established clinical scale (14) as follows: 1, no signs; 2, ruffled fur/and or abnormal posture; 3, lethargy; 4, reduced responsiveness to stimulation and/or ataxia and/or respiratory distress/hyperventilation; and 5, prostration and/or paralysis and/or convulsions. Stages 2 and 3 were classified as pre-dromal ECM, and stages 4 and 5 were classified as ECM. P. berghei ANKA-infected mice were euthanized when they reached stage 4/5 (typically day 7 of infection).

Flow cytometry. Spleens were obtained from infected and uninfected mice. Single-cell suspensions were prepared by homogenizing the tissue through a 70-μm cell strainer (BD Biosciences). Following intracardiac perfusion with 10 ml phosphate-buffered saline (PBS), brains were removed from mice, finely chopped, and incubated with 2 mg/ml collagenase D (Sigma) and 28 U/ml DNase for 30 min at 37°C on a tube roller. The suspension was filtered through a 70-μm cell sieve and centrifuged, and the pellet was resuspended in 15 ml 37% Percoll solution and centrifuged at 2,000 × g for 10 min. The myelin layer was removed, and the sample was washed in fluorescence-activated cell sorting (FACS) buffer (Hanks balanced salt solution [HBSS] with 2% fetal calf serum [FCS]). Red blood cells (RBCs) were lysed in spleen and brain samples by the addition of BD RBC lye (BD Biosciences), and the samples were washed and resuspended in FACS buffer.

The samples were then surface stained with anti-mouse antibodies against CD4 (GX1.5), CD8 (53-6.7), CD11b (M1/70), Ly6G (HK1.4), Ly6C (RB6.8C5), CD11c (N418), CD3 (17A2), F4-80 (BM8), ICOS (C398.4A), KLRG-1 (2F1), CD40 (1C10), CD31 (390), Sca-1 (D7), CD45 (30-F11), and MHC class I (H-2Kb/H-2Db; clone 28-8-6), and CD54 (ICAM-I; clone YN1/1.7.4). All antibodies were from eBioscience, Biolegend, or R&D Systems. Fluorescence-minus-one (FMO) controls were performed to validate antibody staining. Data acquisition was performed using an LSR II instrument (BD Systems, United Kingdom), and analysis was performed using FlowJo software (Tree Star, Inc., Ashland, OR, USA).

NanoString. Brains were removed from infected and uninfected mice following intracardiac perfusion with PBS. The brains were bisected, snap-frozen in liquid N<sub>2</sub>, and stored at −80°C until required. RNA was extracted from the half brains using the RNeasy lipid tissue kit (Qiagen) according to the manufacturer’s guidelines. The nCounter gene expression assay (NanoString Technologies, Seattle, WA, USA) was performed according to the manufacturer’s instructions. Briefly, 100 ng of RNA was hybridized with the reporter and capture probe sets at 65°C overnight. Unhybridized probes were removed via an automated purification performed on the nCounter preparation station, and the resulting target-probe complexes were deposited and bound to the imaging surface. Voltage was applied to elongate and align the molecules, which were then immobilized for imaging. Images were acquired using the nCounter digital analyzer, up to a maximum resolution of 555 fields of view (FOV) per sample. Transcript counts were normalized to the transcription of relevant housekeeping genes using nSolver Analysis software (version 2.5; NanoString Technologies).

In vitro activation of brain endothelial cells. Cells from the murine brain endothelial cell line bEnd5 were seeded in a 24-well plate at 0.1 × 10<sup>4</sup> cell density/well and stimulated for 24 h with 1 ng/ml IFN-γ and/or 1 ng/ml TNF. Cell activation was measured by flow cytometry, as described above. Cells were detached using StemPro Accutase cell dissociation reagent (Thermo Fisher Scientific). The samples were stained with the fixable viability dye eFlour 780 (eBioscience), followed by surface staining with anti-mouse antibodies against CD106 (VCAM-I; clone 429), CD11b (M1/70), Ly6C (HK1.4), Ly6G (RB6.8C5), CD11c (N418), CD3 (17A2), F4-80 (BM8), ICOS (C398.4A), KLRG-1 (2F1), CD40 (1C10), CD31 (390), Sca-1 (D7), CD45 (30-F11), and MHC class I (H-2Kb/H-2Db; clone 28-8-6), and CD54 (ICAM-I; clone YN1/1.7.4). All antibodies were from eBioscience or Biolegend.

ELISA. The expression of IL-6 by bEnd5 cells activated in vitro by IFN-γ and/or TNF was measured from cell supernatants using an IL-6 enzyme-linked immunosorbent assay (ELISA) (R&D systems), following the manufacturer’s instructions. Optical densities were read in a plate reader at 450 nm, with correction for baseline at 570 nm (Synergy HT plate reader; BioTek). The concentrations of the samples were determined by interpolating from a standard curve fitted by sigmoidal equation.
Statistical analysis. Data were checked for normality using the Shapiro-Wilk test. For two-group comparisons, statistical significance was determined using the t test (parametric data) or Mann-Whitney test (nonparametric data). For comparisons of three or more groups, statistical significance was determined using one-way or two-way analysis of variance (ANOVA) with Tukey’s post hoc analysis (parametric data) or the Kruskal-Wallis test with Dunn’s post hoc test (nonparametric data). Results were considered significantly different when the P value was <0.05.

ACKNOWLEDGMENTS

We thank Michal Smiga from the Genomics Technologies Core Facility for help performing the NanoString analyses. We thank Bill Moser, University of Manchester, for help with breeding and genotyping of the animals.

REFERENCES

1. de Souza JB, Hafalla JC, Riley EM, Couper KN. 2010. Cerebral malaria: why experimental murine models are required to understand the pathogenesis of the disease. Parasitology 137:755–772. https://doi.org/10.1017/S0031182009991715.
2. Frewer U, Nacer A. 2014. Fatal cerebral malaria: a venous efflux problem. Front Cell Infect Microbiol 4:155. https://doi.org/10.3389/fcimb.2014.00115.
3. Carvalho LJ, Moreira AD, Daniel-Ribeiro CT, Martins YC. 2014. Vascular dysfunction as a target for adjuvant therapy in cerebral malaria. Mem Inst Oswaldo Cruz 109:574–588. https://doi.org/10.1590/00763136-2014.
4. Hansen DS. 2012. Inflammatory responses associated with the induction of cerebral malaria: lessons from experimental murine models. PLoS Pathog 8:e1003045. https://doi.org/10.1371/journal.ppat.1003045.
5. Hunt NH, Ball HJ, Hansen AM, Khaw LT, Guo J, Bakmiwwe S, Mitchell AJ, Combes V, Grau GE. 2014. Cerebral malaria: gamma-interferon redux. Front Cell Infect Microbiol 4:113. https://doi.org/10.3389/fcimb.2014.00113.
6. Amani V, Vigario AM, Belnoue E, Marussig M, Fonseca L, Mazier D, Renia L. 2000. Involvement of IFN-gamma receptor-mediated signaling in pathology and anti-malarial immunity induced by Plasmodium berghei infection. Eur J Immunol 30:1646–1655. https://doi.org/10.1002/1521-0011.30063.0616.
7. Belnoue E, Potter SM, Rosa DS, Mauduit M, Gruner AC, Kaybanda M, Mitchell AJ, Hunt NH, Renia L. 2008. Control of pathogenic CD8+ T cell migration to the brain by IFN-gamma during experimental cerebral malaria. Parasite Immunol 30:544–553. https://doi.org/10.1111/j.1365-3028.2008.01053.x.
8. Yanez DM, Manning DD, Cooley AJ, Weidanz WP, van der Heyde HC. 1996. Participation of lymphocyte subpopulations in the pathogenesis of experimental murine cerebral malaria. J Immunol 157:1620–1624.
9. Claser C, Malleret B, Gun SY, Wong AY, Chang ZW, Teo P, See PC, Howland SW, Vitek F, Renia L. 2011. CD8+ T cells and IFN-gamma mediate the time-dependent accumulation of infected red blood cells in deep organs during experimental cerebral malaria. PLoS One 6:e18720. https://doi.org/10.1371/journal.pone.0018720.
10. Amante FH, Haque A, Stanley AC, Rivera Fde L, Randall LM, Wilson YA, Yeo G, Pieper C, Crabb BS, de Koning-Ward TF, Lundie RJ, Good MF, Papageorgiou IE, Lewen A, Galow LV, Cesetti T, Scheffel J, Regen T, Hanisch UK, Kann O. 2016. TLR4-activated microglia require IFN-gamma for glial cell activation. Neuroscientist 9:10–22. https://doi.org/10.1177/1073858401631368.
11. Villegas-Mendez A, de Souza JB, Murungi L, Hafalla JC, Shw TN, Greig R, Riley EM, Couper KN. 2011. Heterogeneous and tissue-specific regulation of effector T cell responses by IFN-gamma during Plasmodium berghei ANKA infection. J Immunol 187:2885–2897. https://doi.org/10.4049/jimmunol.1100241.
12. van Deenen PE, Deroost K, Van Aelst I, Geurts N, Martens E, Struyf S, Nie LH. 2000. Involvement of IFN-gamma receptor-mediated signaling in cerebral malaria by modulating CD8+ T cell accumulation within the brain. J Immunol 189:968–979. https://doi.org/10.4049/jimmunol.1200688.
13. Schroder K, Hertzog PJ, Ravai T, Hume DA. 2004. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75:163–189. https://doi.org/10.1189/jlb.0603252.
14. Sah A, Jyothi Prasanna S, Chandrasekar B, Nandi D. 2010. Gene modulation and immunoregulatory roles of interferon gamma. Cytokine 50:1–14. https://doi.org/10.1016/j.cyto.2009.11.021.
15. Bernabei P, Coccia EM, Rigamonti L, Bosticardo M, Forni G, Pestka S, Krause CD, Battinelli A, Novelli F. 2001. Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J Leukoc Biol 70:950–960.
16. Affkarian M, Sedy JR, Yang J, Jacobson NG, Cereb N, Yang SY, Murphy TL, Murphy KM. 2002. T-bet is a STAT1-induced regulator of IL-12R expression in naïve CD4+ T cells. Nat Immunol 3:549–557. https://doi.org/10.1038/ni794.
17. Schulz EG, Mariani L, Radbruch A, Hofer T. 2009. Sequential polarization and inappropriateness of type 1 T helper lymphocytes by interferon-gamma and interleukin-12. Immunol 36:673–683. https://doi.org/10.1016/j.immuni.2009.03.013.
18. Zhang Y, Apilado R, Coleman J, Ben-Sasson S, Tsang S, Hu-Li J, Paul WE, Huang H. 2001. Interferon gamma stabilizes the T helper cell type 1 phenotype. J Exp Med 194:165–172. https://doi.org/10.1084/jem.194.2.165.
19. Badovinac VP, Tvinnereim AR, Hart JY. 2000. Regulation of antigen-specific CD8+ T cell homeostasis by perforin and interferon-gamma. Science 290:1354–1358. https://doi.org/10.1126/science.290.5495.1354.
20. Dalton DK, Haynes L, Chu CQ, Swain SL, Wittmer S. 2000. Interferon gamma elicits responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J Exp Med 192:117–122. https://doi.org/10.1084/jem.192.1.117.
21. Whitmore JKK, Weiss A, Whittington JL, Vitek F. 2000. Interferon-gamma acts directly on CD8+ T cells to increase their abundance during virus infection. J Exp Med 201:1053–1059. https://doi.org/10.1084/jem.20041463.
22. Zhu J, Jankovic D, Oler AJ, Wei G, Sharma S, Hu G, Guo L, Yagi R, Yamane H, Punksodiy G, Feigenbaum L, Zhao K, Paul WE. 2012. The transcription factor T-bet is induced by multiple pathways and prevents an endogenous Th2 cell program during Th1 cell responses. Immunity 37:660–673. https://doi.org/10.1016/j.immuni.2012.09.007.
23. Mizuno T, Zhang G, Takeuchi H, Kawanokuchi J, Wang J, Sonobe Y, Jin S, Takada N, Komatsu Y, Suzumura A. 2008. Interferon-gamma directly induces neurotoxicity through a neuron specific, calcium-permeable complex of IFN-gamma receptor and AMPA GluR1 receptor. FASEB J 22:1797–1806. https://doi.org/10.1096/fj.07-099499.
24. John GR, Lee SC, Brosnan CF. 2003. Cytokines: powerful regulators of glial cell activation. Neuroscientist 9:10–22. https://doi.org/10.1177/1073858402239587.
25. Papageorgiou IE, Lewen A, Galow LV, Cesetti T, Scheffel J, Regen T, Hanisch UK, Kann O. 2016. TLR4-activated microglia require IFN-gamma to induce severe neuronal dysfunction and death in situ. Proc Natl Acad Sci U S A 113:212–217. https://doi.org/10.1073/pnas.1513853113.
26. Bakmiwwe SM, Weiser S, Grey M, Heng B, Guillen GJ, Ball HJ, Hunt NH. 2016. Synergistic induction of Cxcl10 by interferon-gamma and lymphotixin-alpha in astrocytes: possible role in cerebral malaria. Cyto kine 78:79–86. https://doi.org/10.1016/j.cytokine.2015.11.024.
27. Carter SL, Muller M, Manders PM, Campbell IJ. 2007. Induction of the genes for Cxcl9 and Cxcl10 is dependent on IFN-gamma but shows...
differential cellular expression in experimental autoimmune encephalomyelitis and by astrocytes and microglia in vitro. Glia 55:1728–1739. https://doi.org/10.1002/glia.20587.

30. Ng CT, Fong LY, Sulaiman MR, Moklas MA, Yong YK, Hakim MN, Ahmad Z. 2015. Interferon-gamma increases endothelial permeability by causing activation of p38 MAP kinase and actin cytoskeleton alteration. J Interferon Cytokine Res 35:513–522. https://doi.org/10.1016/j.jirc.2014.01.018.

31. Lee HM, Fleige A, Forman R, Cho S, Khan AA, Lin LL, Nguyen DT, O’Hara-Hall A, Yin Z, Hunter CA, Moller W, Lu LF. 2015. IFNgamma signaling endows DCs with the capacity to control type I inflammation during parasitic infection through promoting T-bet+ regulatory T cells. PLoS Pathog 11:e1004635. https://doi.org/10.1371/journal.ppat.1004635.

32. Howland SW, Claser C, Poh CM, Gun SY, Renia L. 2015. Pathogenic CD8+ T cells in experimental cerebral malaria. Semin Immunopathol 37:221–231. https://doi.org/10.1007/s00281-015-0476-6.

33. Penet MF, Viola A, Confort-Gouyoun S, Le Fur Y, Duhamel G, Kober F, Ibarrola D, Izquierdo M, Coltel N, Gharib B, Grau GE, Cozzone PJ. 2005. Imaging experimental cerebral malaria in vivo: significant role of ischemic brain edema. J Neurosci 25:7352–7358. https://doi.org/10.1523/JNEUROSCI.1005-05.2005.

34. Isaka F, Ishibashi M, Taki W, Hashimoto N, Nakashima S, Kageyama R. 1999. Ectopic expression of the bHLH gene Math1 disturbs neural development. Eur J Neurosci 11:2582–2588. https://doi.org/10.1046/j.1460-9586.1999.00699.x.

35. Di Malta C, Fryer JD, Settembre C, Ballabio A. 2012. Astrocyte dysfunction triggers neurodegeneration in a lysosomal storage disorder. Proc Natl Acad Sci U S A 109:E2334–E2342. https://doi.org/10.1073/pnas.1200577109.

36. Renia L, Howland SW, Claser C, Charlotte Gruner A, Suwanarusk R, Hui Teo T, Russell B, Ng LF. 2012. Cerebral malaria: mysteries at the blood-brain barrier. Virulence 3:193–201. https://doi.org/10.4161/viru.19013.

37. Wylot B, Konarzewska K, Bugarski J, Piwocka K, Wadzawka M. 2015. Isolation of vascular endothelial cells from intact and injured murine brain cortex-technical issues and pitfalls in FACS analysis of the nervous tissue. Cytometry A 87:908–920. https://doi.org/10.1002/cyto.a.22677.

38. Shaw TN, Stewart-Hutchinson PJ, Strangward P, Dandamudi DB, Coles JA, Villegas-Mendez A, Brewer JM, Couper KN, Dustin ML. 2015. Perivascular arrest of CD8+ T cells is a signature of experimental cerebral malaria. PLoS Pathog 11:e1005210. https://doi.org/10.1371/journal.ppat.1005210.

39. Belhoue E, Kayibanda M, Vigario AM, Deschenic JC, van Rooijen N, Viguer M, Sounougu G, Renia L. 2002. On the pathogenic role of brain-sequestered alphabeta CD8+ T cells in experimental cerebral malaria. J Immunol 169:6369–6375. https://doi.org/10.4049/jimmunol.169.11.6369.

40. Pai S, Qiu J, Cavanagh L, Mitchell A, El-Assaad F, Jain R, Combes V, Hunt NH, Grau GE, Weninger W. 2014. Real-time imaging reveals the dynamics of leukocyte behaviour during experimental cerebral malaria pathogenesis. PLoS Pathog 10:e1004236. https://doi.org/10.1371/journal.ppat.1004236.

41. Goldmann T, Wieghofer P, Muller PF, Wolf Y, Varol D, Yona S, Brendefee SM, Klerdorff K, Staszewski O, Datta M, Luedde T, Heikenwalder M, Jung S, Prinz M. 2013. A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat Neurosci 16:1618–1626. https://doi.org/10.1038/nn.3531.

42. Wang J, Wegener JE, Huang TW, Srithiyapong S, De Jesus-Cortes H, Xu P, Tran S, Knobbe W, Leko V, Britt J, Stanwalt R, McDaniel L, Ward CS, Parra D, Newcomb B, Lao U, Nouriag M, Flowers DA, Cullen S, Jorstad NL, Yang Y, Glaskova L, Vingeau S, Kozlitina J, Yetman MJ, Jankowsky JL, Reicheard SD, Reicheard HM, Gartner J, Bartolomei MS, Fang M, Loe K, Keene CD, Bernstein I, Goodell M, Brat DJ, Huppek P, Neu J, Bedalov A, Pieper AA. 2015. Wild-type microglia do not reverse pathology in mouse models of Rett syndrome. Nature 521:E1–E4. https://doi.org/10.1038/nature14444.

43. Parkhurst CN, Yang G, Nian N, Savas JN, Yates JR, III, Laflaille JH, Hempstead BL, Littman DR, Gan WB. 2013. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 155:1596–1609. https://doi.org/10.1016/j.cell.2013.11.030.

44. Wheway J, Obeid S, Couraud PO, Combes V, Grau GE. 2013. The brain microvascular endothelium supports T cell proliferation and has potential for alloantigen presentation. PLoS One 8:e52586. https://doi.org/10.1371/journal.pone.0052586.

45. Siegemund S, Shepherd J, Xiao C, Sauer K. 2015. HCD2-iCre and Vav-iCre mediated gene recombination patterns in murine hematopoietic cells. PLoS One 10:e0124661. https://doi.org/10.1371/journal.pone.0124661.

46. Swanson PA, II, Hart GT, Russo MV, Nayak D, Yazew T, Pena M, Khan SM, Janse CJ, Pierce SK, McGavern DB. 2016. CD8+ T cells induce fatal brainstem pathology during cerebral malaria via luminal antigen-specific engagement of brain vasculature. PLoS Pathog 12:e1006022. https://doi.org/10.1371/journal.ppat.1006022.

47. Ridder DA, Lang MF, Salinir S, Roderer JP, Struss M, Maser-Bluth C, Schwaninger M. 2011. TAK1 in brain endothelial cells mediates fever and lethargy. J Exp Med 208:2615–2623. https://doi.org/10.1084/jem.20110398.

48. de Boer J, Williams A, Skavdis G, Harker N, Coles M, Tolaini M, Norton T, Williams K, Roderick K, Potocnik AJ, Kiousis D. 2003. Transgenic mice with hematopoietic and lymphoid specific expression of the Cet. Eur J Immunol 33:314–325. https://doi.org/10.1002/jimm.200310005.

49. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I. 1999. Conditional gene targeting in macrophages and granulocytes using LysMCre mice. Transgenic Res 8:265–277. https://doi.org/10.1007/A100894282960.

50. Lee PP, Fitzpatrick DR, Beard C, Jessup HK, Lehar S, Makar KW, Perez-Melgosia M, Sweetser MT, Schlissel MS, Nguyen S, Cherry SR, Tsai JH, Tucker SM, Weaver WM, Kelso A, Jaenisch R, Wilson CB. 2001. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 15:763–774. https://doi.org/10.1016/S1074-7613(01)00227-8.

51. Georgiades P, Ogilvy S, Duval H, Licence DR, Charnock-Jones DS, Smith SK, Print CG. 2002. VavCre transgenic mice: a tool for mutagenesis in hematopoietic and endothelial lineages. Genesis 34:251–256. https://doi.org/10.1002/gene.10161.

52. Parliament of the United Kingdom. 1986. Animals (Scientific Procedures) Act 1986 (c. 14) (as amended). http://www.legislation.gov.uk/ukpga/1986/14.

53. Franke-Fayard B, Trueman H, Ramesar J, Mendoza J, van der Keur M, van der Linden R, Sinden RE, Waters AP, Janse CJ. 2004. A Plasmidium berghei reference line that constitutively expresses GFP at a high level throughout the complete life cycle. Mol Biochem Parasitol 137:23–33. https://doi.org/10.1016/j.molbiopara.2004.04.007.